Seattle Genetics, Inc. today announced that Health Canada has issued a Notice of Compliance with conditions , authorizing marketing of ADCETRIS for two lymphoma indications: the treatment of patients with Hodgkin lymphoma after failure of autologous stem cell transplant or after failure of at least two multi-agent chemotherapy regimens in patients ... (more)
http://www.freshnews.com/news/755328/health-canada-approves-adcetris-brentuximab-vedotin-treatment-relapsed-or-refractory-ho
http://www.freshnews.com/news/755328/health-canada-approves-adcetris-brentuximab-vedotin-treatment-relapsed-or-refractory-ho
No comments:
Post a Comment